SD BIOSENSOR INC.
Financials
Valuation Metrics
SD BIOSENSOR INC.'s Market Cap is ₩7945B. At end of 2025 it was ₩1.1T. Ranked #324 of 2,436 in KR market (top 13%), #235 of 787 on KOSPI (top 30%), #8 of 96 in Health Care Equipment & Services (top 8%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 794.53B KRW | KR#324/2,436 Sec#8/96 |
| Revenue | 718.78B KRW | KR#481/2,436 Sec#4/96 |
| Net Income | -472.26B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 2.95T KRW | KR#235/2,436 Sec#1/96 |
| Net Assets | 2.37T KRW | KR#154/2,436 Sec#1/96 |
| Employees | 613 | KR#406/2,436 Sec#6/96 |
| Value | ||
| P/B | 0.33x | KR#411/2,436 Sec#6/96 |
| P/S | 1.11x | KR#1,477/2,436 Sec#34/96 |
| FCF Yield | 37.81% | KR#144/2,436 Sec#3/96 |
| Profitability | ||
| ROE | -19.89% | KR#2,073/2,436 Sec#73/96 |
| ROA | -16.04% | KR#2,190/2,436 Sec#76/96 |
| Op. Margin | -10.84% | KR#2,001/2,436 Sec#64/96 |
| Revenue Growth | 4.43% | KR#1,192/2,436 Sec#59/96 |
| Financial Health | ||
| Debt Ratio | 124.06% | KR#750/2,436 Sec#36/96 |
| Total Debt | 587.08B KRW | KR#273/2,436 Sec#2/96 |
| FCF | 300.43B KRW | KR#87/2,436 Sec#1/96 |
| Cash | 184.19B KRW | KR#288/2,436 Sec#2/96 |
| Current Ratio | 5.07x | KR#288/2,436 Sec#23/96 |
| Dividend | ||
| Div. Yield | 3.10% | KR#635/2,436 Sec#8/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -33.87% | KR#1,642/2,436 Sec#51/96 |
| 1M Return | 0.61% | KR#753/2,436 Sec#31/96 |
| From 52W High | -39.80% | KR#713/2,436 Sec#24/96 |
| 1Y MDD | -47.31% | KR#804/2,436 Sec#26/96 |
| Trading | ||
| Volume | 96,611 shares | KR#829/2,436 Sec#34/96 |
| Foreign Own. | 6.30% | KR#684/2,436 Sec#20/96 |
| Per Share | ||
| EPS | -3,868 KRW | KR—/2,436 Sec—/96 |
| BPS | 19,793 KRW | KR#514/2,436 Sec#8/96 |
Company Info
SD BIOSENSOR, established in 2010 as a spin-off from SD Co., Ltd.'s biosensor division, is a mid-sized company as of 2024. The company primarily focuses on R&D and sales of in-vitro diagnostics, including immunochemistry, molecular, point-of-care, and self-blood glucose monitoring. SD BIOSENSOR is expanding its global market and portfolio through a network of over 100 exclusive dealers, direct sales in key countries, and quality competitiveness, including WHO PQ approval. Headquartered in Suwon, Gyeonggi-do, it was founded in 2010.